Baroreflex sensitivity associated hypoalgesia in healthy states is altered by chronic pain

Chung, Ok Yung; Bruehl, Stephen; Diedrich, Laura; Diedrich, André; Chont, Melissa; Robertson, David

doi:10.1016/j.pain.2007.11.011

Cited by 64 publications

(71 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…, 19]. A series of four pain threshold trials was conducted, followed by a series of four pain tolerance trials, with the probe applied to a slightly different target site for each trial to avoid local sensitization (procedures are detailed more extensively in [17]). For each tolerance trial, the probe started at an adaptation temperature of 40°C, with the temperature increasing at a ramp rate of 0.5°C/sec until the participant indicated maximum tolerance had been reached.…”

Section: Methodsmentioning

confidence: 99%

“…The current sample included all participants from one completed study [17] and two ongoing studies who met entry criteria for the current study. These criteria were: 1) availability of sufficient DNA for genetic assays, 2) availability of placebo condition acute pain response data, and 3) availability of pain rating data in which no intervention other than placebo administration had occurred prior to the acute pain tasks.…”

Section: Subjectsmentioning

confidence: 99%

“…Subjects were asked to refrain from use of analgesics, NSAIDs, or any medications potentially affecting blood pressure (e.g., pseudoephedrine) for 12 hours prior to study participation and to avoid caffeine 3 hours prior to study participation. Subjects from Chung et al [17] additionally were free of depression and anxiety disorders based on results of a structured clinical interview. The final study sample size was n=87, including 58 subjects from a study employing alpha-2 adrenergic blockade with yohimbine [17], 19 subjects from a study employing opioid blockade with naloxone, and 10 subjects from a study employing opioid blockade with naltrexone.…”

Section: Subjectsmentioning

confidence: 99%

“…Subjects from Chung et al [17] additionally were free of depression and anxiety disorders based on results of a structured clinical interview. The final study sample size was n=87, including 58 subjects from a study employing alpha-2 adrenergic blockade with yohimbine [17], 19 subjects from a study employing opioid blockade with naloxone, and 10 subjects from a study employing opioid blockade with naltrexone. Of the final sample, 60.9% were healthy pain-free controls and 39.1% were individuals with chronic low back pain (median pain duration: 67.4 months; past month visual analog pain intensity: 40.3± 2.88 out of 100mm).…”

Section: Subjectsmentioning

confidence: 99%

See 3 more Smart Citations

The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity

Bruehl

Chung

Burns

2008

Pain

Self Cite

View full text Add to dashboard Cite

Both trait anger-in (managing anger through suppression) and anger-out (managing anger through direct expression) are related to pain responsiveness, but only anger-out effects involve opioid mechanisms. Preliminary work suggested the effects of anger-out on post-operative analgesic requirements were moderated by the A118G single nucleotide polymorphism of the mu opioid receptor gene. This study further explored these potential genotype X phenotype interactions as they impact acute pain sensitivity. Genetic samples and measures of anger-in and anger-out were obtained in 87 subjects (from three studies) who participated in controlled laboratory acute pain tasks (ischemic, finger pressure, thermal). McGill Pain Questionnaire (MPQ) Sensory and Affective ratings for each pain task were standardized within studies, aggregated across pain tasks, and combined for analyses. Significant anger-out X A118G interactions were observed (p's<.05). Simple effects tests for both pain measures revealed that whereas anger-out was nonsignificantly hyperalgesic in subjects homozygous for the wild-type allele, anger-out was significantly hypoalgesic in those with the variant G allele (p's<.05). For the MPQ-Affective measure, this interaction arose both from low pain sensitivity in high anger-out subjects with the G allele and heightened pain sensitivity in low anger-out subjects with the G allele relative to responses in homozygous wild-type subjects. No genetic moderation was observed for anger-in, although significant main effects on MPQ-Affective ratings were noted (p<.005). Anger-in main effects were due to overlap with negative affect, but anger-out X A118G interactions were not, suggesting unique effects of expressive anger regulation. Results support opioid-related genotype X phenotype interactions involving trait anger-out.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Subjectsmentioning

confidence: 99%

Section: Subjectsmentioning

confidence: 99%

Section: Subjectsmentioning

confidence: 99%

See 2 more Smart Citations

The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity

Bruehl

Chung

Burns

2008

Pain

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chung и соавт. [48] показали, что у пациентов с хронической болью в спине значительно ниже уровень вариабельности сердечного ритма в покое и при ортостатической нагрузке. Схожий паттерн вариа-бельности сердечного ритма обнаружен у пациентов с фи-бромиалгией [49].…”

Section: л е к ц и яunclassified

Migraine and hypertension

Tabeeva

Muranova

Кострыгина

et al. 2015

RJTAO

View full text Add to dashboard Cite

Взаимосвязь мигрени и сердечно-сосудистых заболе-ваний (ССЗ) изучается в течение многих лет. В 1975 г. был опубликован системный обзор, в котором показано досто-верное увеличение риска развития ишемического инсульта у молодых женщин с мигренью на фоне курения и приема оральных гормональных контрацептивов [1]. В последую-щем были получены убедительные данные, доказывающие, что мигрень с аурой (МА) является самостоятельным фак-тором риска развития ишемического инсульта, субклиниче-ского поражения белого вещества головного мозга и рети-нопатии, что особенно выражено у женщин молодого воз-раста [2][3][4]. Последние результаты клинических и эпиде-миологических исследований показывают, что МА является фактором риска не только ишемического поражения голов-ного мозга, но и ишемической болезни сердца (ИБС), ин-фаркта миокарда (ИМ) и стенокардии. При этом повыше-ние риска развития кардиоваскулярной патологии отмече-но и у пациентов с мигренью без ауры (МБА), а также в мужской популяции [5]. Несмотря на длительную историю изучения взаимосвязи мигрени и артериальной гипертен-зии (АГ), полученные результаты противоречивы и требуют дальнейшего углубленного исследования и интерпретации. Л Е К Ц И Я

show abstract

The MOBID‐2 pain scale: Reliability and responsiveness to pain in patients with dementia

Husebø

Ostelo

Strand

2014

European Journal of Pain

View full text Add to dashboard Cite

BackgroundMobilization-Observation-Behavior-Intensity-Dementia-2 (MOBID-2) pain scale is a staff-administered pain tool for patients with dementia. This study explores MOBID-2's test–retest reliability, measurement error and responsiveness to change.MethodsAnalyses are based upon data from a cluster randomized trial including 352 patients with advanced dementia from 18 Norwegian nursing homes. Test–retest reliability between baseline and week 2 (n = 163), and weeks 2 and 4 (n = 159) was examined in patients not expected to change (controls), using intraclass correlation coefficient (ICC2.1), standard error of measurement (SEM) and smallest detectable change (SDC). Responsiveness was examined by testing six priori-formulated hypotheses about the association between change scores on MOBID-2 and other outcome measures.ResultsICCs of the total MOBID-2 scores were 0.81 (0–2 weeks) and 0.85 (2–4 weeks). SEM and SDC were 1.9 and 3.1 (0–2 weeks) and 1.4 and 2.3 (2–4 weeks), respectively. Five out of six hypotheses were confirmed: MOBID-2 discriminated (p < 0.001) between change in patients with and without a stepwise protocol for treatment of pain (SPTP). Moderate association (r = 0.35) was demonstrated with Cohen-Mansfield Agitation Inventory, and no association with Mini-Mental State Examination, Functional Assessment Staging and Activity of Daily Living. Expected associations between change scores of MOBID-2 and Neuropsychiatric Inventory – Nursing Home version were not confirmed.ConclusionThe SEM and SDC in connection with the MOBID-2 pain scale indicate that the instrument is responsive to a decrease in pain after a SPTP. Satisfactory test–retest reliability across test periods was demonstrated. Change scores ≥ 3 on total and subscales are clinically relevant and are beyond measurement error.

show abstract

Baroreflex sensitivity associated hypoalgesia in healthy states is altered by chronic pain

Cited by 64 publications

References 52 publications

The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity

The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity

Migraine and hypertension

The MOBID‐2 pain scale: Reliability and responsiveness to pain in patients with dementia

Contact Info

Product

Resources

About